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Objectives:  The  authors  present  the  guidelines  of  the  French  Oto-Rhino-Laryngology-  Head  and  Neck
Surgery  Society  (Société  franc¸ aise  d’oto-rhino-laryngologie  et  de  chirurgie  de  la face et du  cou  [SFORL])
for  the management  of  somatic  pain  induced  by head-and-neck  cancer  treatment,  and in particular  the
instruments  needed  for  the  deﬁnition  and  initial  assessment  of  the  various  types  of  pain.
Methods:  A  multidisciplinary  work  group  was  entrusted  with  a review  of  the  scientiﬁc  literature  on
the  above  topic.  Guidelines  were  drawn  up, based  on  the  articles  retrieved  and  the  group  members’
individual  experience.  They  were  then  read over  by an  editorial  group  independent  of the work  group.
The  ﬁnal  version  was  established  in  a coordination  meeting.  The  guidelines  were  graded  as  A, B,  C  or
expert  opinion,  by  decreasing  level  of evidence.
Results: The  priority  is  to  eliminate  tumoral  recurrence  when  pain  reappears  or changes  following  head-
and-neck  cancer  treatment.  Neuropathic  pain  screening  instruments  and  pain  assessment  scales  should
be  used  to assess  pain  intensity  and  treatment  efﬁcacy.  Functional  rehabilitation  sessions  should  be
prescribed  to  reduce  musculoskeletal  pain  and  prevent  ankylosis  and  postural  disorder.  Psychotherapy
and  mind-body  therapy,  when  available,  should  be  provided  in  case  of  chronic  pain.  In  case  of  recalcitrant
complex  pain,  referral  should  be made  to a  multidisciplinary  pain  structure.
Conclusion:  The  management  of  somatic  pain  induced  by  head-and-neck  cancer  treatment  above  all
requires  identifying  and  assessing  the intensity  of the various  types  of pain  involved,  their  functional
impact  and their  emotional  component.
©  2014  Elsevier  Masson  SAS.  All  rights  reserved.∗ Corresponding author.
E-mail address: marie.binczak@gmail.com (M. Binczak).
http://dx.doi.org/10.1016/j.anorl.2014.07.003
879-7296/© 2014 Elsevier Masson SAS. All rights reserved.1. IntroductionIn head and neck oncology, pain is often a tumor-revealing
symptom. In most cases, treatment and cure of the cancer will
relieve or abolish pain: persistence, recurrence or change in
type suggests evolution or recurrence of the disease [1] (level
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f evidence 2). Even when complete cure is achieved, treatment
chemotherapy, surgery, radiation therapy) is heavy and may
eave esthetic, functional, psychological and painful sequelae. All
hese components enter into the assessment and management of
reatment-induced pain.
The present guidelines seek to provide the practitioner with
he toolbox required for the deﬁnition and initial assessment of
he various types of pain induced by head-and-neck cancer treat-
ent.
. Method
A multidisciplinary work group was set up and entrusted with a
eview of the scientiﬁc literature on the study topic. The group met
everal times and drew up a position paper as a basis for guidelines.
he resultant texts were read over by an editorial group indepen-
ent of the work group. The ﬁnal version of the guidelines was
rawn up in a coordination meeting.
Guidelines were graded A, B or C according to decreasing
evel of evidence, following the literature analysis and guideline
rading guide published by the ANAES national health accredita-
ion and assessment agency. Where no precise level of evidence
ould be stipulated, the guideline was classiﬁed as an expert
pinion, derived from discussion between work group mem-
ers.
. Guidelines
.1. Deﬁnition of pain
.1.1. Acute pain, chronic pain
Pain is deﬁned as “an unpleasant sensory and emotional experi-
nce associated with actual or potential tissue damage, or described
n terms of such damage” [2] (level of evidence 1). Acute pain is a
ymptom, serving a biological function of protection (alarm signal)
3] (level of evidence 1). It contributes to etiologic diagnosis, and
ecreases and resolves when etiologic treatment is implemented.
Chronic pain is a multidimensional syndrome expressed by the
ictim (“pain disease”). The term “chronic pain” applies in case of
everal of the following criteria: persistence or recurrence, last-
ng longer than usual for the presumed initial cause, especially
hen evolving for more than 3 months; insufﬁcient response to
reatment; signiﬁcant progressive deterioration due to pain in func-
ional and relational capacity in daily activity, at home or at work
4] (level of evidence 1). Assessment should take account of the var-
ous resulting psychological and behavioral factors and treatment
hould include psychogenic and social factors if it is to be effective
2] (level of evidence 1).
“Sentinel” pain is a pain that recurs or changes, raising the difﬁ-
ult problem of differential diagnosis between tumoral recurrence
nd treatment sequela. Clinical, endoscopic and/or imaging inves-
igation is required [5] (Expert opinion).
Guideline 1
It is recommended to give priority to removing recurrent
tumor in case of pain reappearing or changing following head-
and-neck cancer treatment (Expert opinion).
.2. The various types of painCancer treatment-induced pain is particularly complex and
ultidimensional. It includes nociceptive, neuropathic and mixed
omponents at multiple locations. There is systematic speciﬁcgy, Head and Neck diseases 131 (2014) 243–247
psychological suffering related to disturbance of essential func-
tions (language, swallowing, body image) and their psychosocial
consequences. Precisely diagnosing the respective roles of these
mechanisms, with their speciﬁc treatments, is essential for
efﬁcacy.
3.2.1. Nociceptive pain
Pain due to excessive nociception results from overstimula-
tion of the head and neck nociceptive system, due to tumor
expansion and inﬂammation (compression, ischemia, infection,
destruction of tissue structures releasing algogenic substances,
etc.) and to the speciﬁc type of treatment (surgery, radiation ther-
apy, chemotherapy). Chemotherapy and radiation therapy cause
severe pain (mucositis, post-radiation necrosis, etc.). Nocicep-
tive pain responds to analgesia, which reduces or interrupts the
transmission of nociceptive messages at peripheral (NSAIDs, corti-
costeroids) and/or central level (paracetamol, opioids) [6] (Expert
opinion).
Temporal pain analysis distinguishes between background pain,
present almost continuously, and paroxysmal pain, which is a
transient increase in intensity. Paroxysmal pain usually lasts less
than 10 minutes and does not exceed 1 hour; it requires pow-
erful, fast-acting treatment. It may  be predictable, triggered by
feeding, swallowing, dressings, neck movement, etc., or occur
spontaneously. In case of more than 4 episodes per day, the main-
tenance regimen should be reconsidered [7] (level of evidence
4).
3.2.2. Neuropathic pain
Neuropathic pain is secondary to a peripheral or central ner-
vous system lesion, altering the nociceptive transmission and/or
control processes. In head and neck cancer, it is mainly peripheral.
It can also be caused by distal demyelinization in certain cura-
tive treatments (platinum or taxane based chemotherapy) and is
exacerbated by underlying alcohol-related neuropathy [8] (level of
evidence 4).
Neuropathic, like nociceptive, pain may  be localized or pro-
jected (hemicrania continua, reﬂex otalgia, neck pain, etc.). It may
be exacerbated by neurovascular or cerebral mechanisms. This con-
vergence also explains the reﬂex muscular responses (contracture,
trismus, etc.) and the involvement of the vigilance and emotional
systems (tension headache, anxiety, depressive syndrome, etc.).
Ortho- and para-sympathetic innervation, depending on the cranial
nerves, explains vasomotor headache.
3.2.3. Musculotendinous pain
Sequellar pain localized in the neck and shoulder region
concerns more than one-third of patients. There are various mech-
anisms: neuropathic, as described above; myofascial, related to
post-radiation ﬁbrosis or myocutaneous ﬂap reconstruction; or
articular, in the cervical, scapular or temporomandibular joints [9]
(level of evidence 3).
Guideline 2
Functional rehabilitation should be prescribed to reduce
musculoskeletal pain, prevent ankylosis and postural disorder,
and restore functional capacity (Expert opinion).
Accessory nerve palsy (XIth cranial nerve) may  occur in neck dis-
section. Frequency and severity depend on the type of dissection
[10,11] (level of evidence 3) and are increased by postoperative
radiation therapy. Scapulohumeral pain is severe, of mechani-
cal origin; abduction is impaired, at < 90◦, the shoulder falls and
the shoulder blade becomes detached. The pain is caused by
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tretching of the angular muscle and by subacromial impinge-
ent, leading even to retractile capsulitis [11] (level of evidence
).
.2.4. Psychological components
Pain is a multidimensional experience: sensory, emotional,
ehavioral and cognitive. It is initially experienced as a somatic
vent with behavioral impact: the alarm signal of pain leads to
ehavioral patterns of care and protection to attain relief. The
motional aspect is of a general nature: the difﬁculty of spec-
fying it lies in the singularity of the experience of pain. From
he cognitive point of view, pain alters the subject’s percep-
ion of the environment. In the literature of cognitive-behavioral
heory, such perceptions or “beliefs” are described as presuppo-
itions acting as a ﬁlter or matrix of the interpretation of reality,
ffecting the behavior of patients in pain [12] (level of evidence
).
Correlated to such psychological vulnerability, the patient may
atastrophize, showing a pattern of pessimistic thought, expecta-
ion and representation that mediates the attention paid to the
ain. The representations common to head and neck cancers (dis-
guration, asphyxia, hemorrhage) are associated with a fear of
uffering and the expectation of fatal outcome [13] (Expert opin-
on).
Onset or persistence of pain may  cause psychological distress to
he point of adaptation disorder or anxiety and depressive disor-
er.
The same holds for pain and depression. Pain may  cause psycho-
ogical distress, impairing the subject’s coping capacity [14] (Expert
pinion).
Guideline 3
Multidisciplinary pain management should include psy-
chotherapy in case of chronic pain. The techniques (cognitive-
behavioral or psychoanalytic) should be determined by the
patient’s demand and the therapist’s training (Expert opinion).
Guideline 4
When available, mind-body therapy should be proposed,
performed by a trained care professional, for receptive patients
with pain following head and neck cancer treatment (Expert
opinion).
.3. Pain assessment
Pain assessment has various objectives.
The ﬁrst is to conﬁrm the diagnosis of pain experienced by the
atient: this implies “believing the patient” and his or her com-
laint. The second is to quantify the pain. The third is to assess the
peciﬁcities of the respective types of pain and the efﬁcacy of the
ppropriate treatments [15] (level of evidence 1).
Assessment is difﬁcult in patients unable to communicate, and
otably in elderly patients with cognitive disorder. Observational
cales can be implemented by care staff: Doloplus, Algoplus (which
ill soon be available in English) and, in French, the ECPA (Échelle
omportementale pour personnes âgées). Head-and-neck cancer
atients can use all the various self-assessment scales: speech-
elated difﬁculties in no way impair thought and understanding.
inally, assessment and reassessment measures treatment impactgy, Head and Neck diseases 131 (2014) 243–247 245
in terms of efﬁcacy and side-effects, for long-term follow-up of
therapy.
3.3.1. Initial assessment
Initial assessment is in the form of a semi-structured inter-
view [15] (level of evidence 1), collecting patient history, medical
history, curative treatments, evolutive stage, history of pain, modal-
ity of onset, evolutive proﬁle (pain-free/continuous pain interval,
paroxysmal pain), trigger factors (physical or psychological stimu-
lation), and analgesics (efﬁcacy, side-effects and compliance). Also
to be noted are cognitive factors such as expectation with regard
to treatment (miracle drugs), representation of pain (recurrent
and sequellar pain) and beliefs regarding disease and treat-
ment.
3.3.2. Psychometric quantitative assessment
Pain intensity can be measured on three one-dimensional self-
assessment scales which have the same metrologic quality in
terms of validity, sensitivity and reproducibility [16] (level of
evidence 1): the visual analog scale (VAS slide-rule), the numer-
ical Likert scale (ﬁgure between 0 and 10 reported verbally
or on paper), and the simple verbal scale (choice of label to
describe pain (0–4): no pain, weak, moderate, intense or extremely
intense pain). These do not, however, assess the other dimen-
sions of pain or specify diagnosis or mechanism. They do not
enable inter-subject comparison, but are useful for indicating ini-
tiation of treatment (necessitated by VAS > 30 mm;  severe pain
if > 60/100) and for follow-up [15] (level of evidence 1). Mea-
surements should be made at varying times: present, mean level
for the previous week, maximum experienced intensity. Varia-
tion on VAS assesses treatment efﬁcacy. The “beneﬁcial” change
in intensity (i.e., clinically relevant for a therapeutic effect) is a
reduction of 2 points or 30%, associated with a feeling of improve-
ment, as reported in several studies, independently of pathology
or patient age; a reduction of 4 points or > 50% is associated with
a feeling of very great improvement [17–19] (level of evidence
1).
Pain impact and treatment efﬁcacy can also be assessed in terms
of effect on the patient’s pain-related behavior; there are several
such scales, based on the Brief Pain Inventory (BPI) [15–19] (level
of evidence 1). The 6-item French version of the Brief Pain Inventory
(Questionnaire Concis de la Douleur: QCD) [15] (level of evidence
2) measures the impact of pain on sleep, functional capacity, mood,
work, relations with others and enjoyment of life, on a scale from 0
to 10; however, item scores are analyzed separately and the global
sum of item scores is not a valid pain parameter; variations in
BPI item scores have been validated as being relevant in certain
pathologies [16,17] (level of evidence 1).
3.3.3. Multidimensional qualitative pain assessment
The Saint Antoine pain questionnaire (Appendix 1) assesses the
sensory and emotional components of pain [15] (level of evidence
1). Terms describing pain are graded by the patient to assess both
somatic and affective impact and in particular to identify the emo-
tional and neuropathic components on the items “burn”, “electric
shock” and “vise”.
Impact on sleep (one-dimensional categoric or speciﬁc scale
[15] (level of evidence 1)), anxiety and depression associated with
chronic pain is also assessed. Two scales have been validated in
French: the Beck Depression Inventory (BDI), and the Hospital Anx-
iety and Depression scale (HADs) (Appendix 2), which has been
validated for internal medicine, is quick to administer and assesses
the subject’s emotional status in terms of anxiety or depression.
Reduced physical and social function often correlate with a high
anxiety score, and asthenia with a high depression score. Diagnosis
2 yngology, Head and Neck diseases 131 (2014) 243–247
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Peripheral neuropathic pain
Focal lesion Diffuse lesion
Topical treatment
Lidoca ine compress 
(marketing authorization for post -herpes 
zoster pain)
Oral monotherapy
either:
Second step: capsaicin patch
Pregabalin 
Gabapentin
Antidepressants: 
clomipramine 
amitriptyline
Treatment monitoring every 2 weeks / 1 month
Effective
Failure or insufficient or adverse effect:
Change molecule in monotherapy
Or associate 2 drugs of different class
Continue present treatment
Failure or insufficient or adverse effect:
Neurosurgery: 
neurostimulation
Antidepressant serotonin 
or noradrenalin reuptake 
inhibitor
Other antiepileptics
Opioids 
Fig. 1. Treatment algorithm for neuropathic pain.46 M.  Binczak et al. / European Annals of Otorhinolar
nd psychological assessment are often made by interview with a
sychologist or psychiatrist.
.3.4. Speciﬁc assessment of neuropathic pain
Neuropathic pain is diagnosed on a simple instrument such as
he DN4 [20] (level of evidence 1) (Appendix 3) and assessed on
he NPSI (Neuropathic Pain Symptom Inventory), which has been
alidated in French [21] (level of evidence 1) and is sensitive to
hange, with a correlation between change in global score and pain
elief [21] (level of evidence1).
.3.5. Overall assessment of change under treatment
Overall assessment of change under treatment is based on
he patient’s experience, assessing global pain on self-assessment
cales. Perceived change differs widely between patient and physi-
ian and from patient to patient [19] (level of evidence 1).
he 7-point Patients’ Global Impression of Change (PGIC) scale
ncludes a Clinical Global Impression form for patient (CGI-P) and
xaminer (CGI-E) to allow comparison between the two view-
oints.
The evolution of drug intake also reﬂects treatment efﬁcacy.
Compliance and tolerance (side-effects) as assessed from a diary
re good ways of monitoring pain and drug intake. Quality of life
orrelates with level of pain [15,16] (level of evidence 1). The SF 36
uality of life scale or its shorter form (SF12) are the most widely
sed instruments in clinical research, but are difﬁcult to apply
n routine clinical practice. Simpler categoric scales (BPI) may  be
sed.
Guideline 5
Pain assessment scales should be used to assess pain inten-
sity and treatment efﬁcacy (Grade A).
Guideline 6
The DN4 diagnostic scale should be used to identify neu-
ropathic pain so as to prescribe adapted speciﬁc treatment
(Grade A).
.4. Complex recalcitrant pain
In persistent recalcitrant pain resisting clinical analysis and
ell-conducted primary treatment, often with a component of
nxiety and depression as presenting symptom, mistaken inter-
retation and beliefs regarding pain and the disease impair the
octor-patient relationship and thus compliance and treatment
fﬁcacy [4] (Expert opinion).
Management of recalcitrant pain should begin with specialized
nd documented clinical analysis of the various physiopatholo-
ical mechanisms, the patient’s evolutive proﬁle (evolving cancer,
ecurrence, sequelae), assessment of the various components of
ain, their level of intensity and repercussions (sleep, etc.) and
ggravating factors (somatic, sensory disability, anxiety, depres-
ion, emotional suffering, fear of death).
Treatment can be adapted based on this analysis [22] (level of
vidence 3). Recalcitrant pain requires global management, deal-
ng simultaneously with the somatic aspect and psychological and
ocial issues [4] (Expert opinion).From reference [24] (Expert opinion).
Assessment of efﬁcacy, tolerance and compliance allows
subsequent treatment strategy to be adapted. For nocicep-
tive pain, in case of failure, changes should be made in
the drugs (rotation), administration route (parenteral, self-
dosed analgesia), associations with anti-hyperalgesics (ketamine,
etc.), and, if necessary, neurosurgical or interventional radi-
ation techniques (trigeminal thermocoagulation, perimedullary
or central infusion of strong opioids). For neuropathic pain,
second or third-line drugs are introduced according to val-
idated algorithms [22,23] (Expert opinion) (Fig. 1). In all
cases, global management requires multidisciplinary team-
work to draw up a consensual multimodal treatment pro-
gram.
Guideline 7
Complex recalcitrant pain requires global management.
The patient should be referred to a multidisciplinary team (pain
structure) (Expert opinion).
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ppendix 1. Saint Antoine pain questionnaire.
The Questionnaire Douleur Saint Antoine is derived from the
hort-form McGill Pain Questionnaire, below.
Pain Quality None
0
Mild
1
Moderate
2
Severe
3
Throbbing
Shooting
Stabbing
Sharp
Cramping
Gnawing
Hot-burning
Aching
Heavy
Tender
Splitting
Tiring-exhausting
Sickening
Fearful
Punishing-cruel
ppendices 2 and 3. Supplementary data
Supplementary data (Appendices 2 and 3) associated with this
rticle can be found, in the online version, at http://dx.doi.org/
0.1016/j.plantsci.2004.08.011.
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